Congress is making “quiet progress” on lowering drug costs for patients, say pharmaceutical policy experts Kristi Martin and Jeremy Sharp of Waxman Strategies. In their post on To the Point, Martin and Sharp explain how legislation currently moving through Congress could help to lower drug costs for patients by targeting drug company strategies designed to stifle or delay competition.
